-
Product Insights
NewKeratoconjunctivitis – Drugs In Development, 2024
Empower your strategies with our Keratoconjunctivitis – Drugs In Development, 2024 report and make more profitable business decisions. Keratoconjunctivitis sicca (KCS), also known as dry eye syndrome (DES), dry eye disease, and keratitis sicca, is a multifactorial disease of the ocular surface caused by a loss of homeostasis of the tear film. It often results in ocular symptoms and visual disturbance due to underlying tear film instability, ocular surface inflammation and damage, and neurosensory abnormalities. The Keratoconjunctivitis drugs in development market...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Entacingene Turiparvovec in Achromatopsia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Entacingene Turiparvovec in Achromatopsia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Entacingene Turiparvovec in Achromatopsia Drug Details: AAV-CNGB3 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AAV-GAD in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AAV-GAD in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.AAV-GAD in Parkinson's DiseaseDrug Details:AAV-GAD is under development for the treatment of Parkinson's...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Deupirfenidone in Idiopathic Pulmonary Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Deupirfenidone in Idiopathic Pulmonary Fibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Deupirfenidone in Idiopathic Pulmonary Fibrosis Drug Details: Deupirfenidone (SD-560, LYT-100) is under...
-
Company Profile
MeiraGTx Holdings Plc – Company Profile
MeiraGTx Holdings Plc (MeiraGTx) is a gene therapy company that develops treatments for ocular, salivary gland and central nervous system diseases. The company’s product pipeline includes AAV-RPGR, AAV-RPE65, AAV-CNGB3, A006, AAV-GAD, AAV-UPF1 and AAV-AQP1. Its pipeline treats X-linked retinitis pigmentosa, gene deficiency, achromatopsia, macular degeneration, parkinson’s disease, amyotrophic lateral sclerosis, radiation-induced xerostomia and ophthalmology diseases. MeiraGTx is developing riboswitch inducible expression programs targeting ophthalmology and oncology indications, diabetes and metabolic disorders among others. The company operates in the UK, the...
Add to Basket -
Sector Analysis
Head and Neck Squamous Cell Carcinomas (HNSCC) – Cell and Gene Therapies 15-Market Assessment and Sales Forecast to 2031
Head and Neck Squamous Cell Carcinomas (HNSCC) Market Report Overview The total head and neck squamous cell carcinomas market value for the 15M, which includes both cell and gene therapies and established/traditional HNSCC therapies was $1.9 billion in 2021. The following are some of the key highlights of the HNSCC market: The market growth is attributed to the established immune checkpoint inhibitors having a high ACOT. APAC had the highest share in 2021. Head and Neck Squamous Cell Carcinomas (HNSCC)...
-
Product Insights
Retinitis Pigmentosa (Retinitis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Retinitis Pigmentosa (Retinitis) Pipeline Drugs Market Report Overview Retinitis Pigmentosa (RP) refers to a group of diseases that cause a slow but progressive vision loss. Retinitis pigmentosa is caused by a genetic defect. Symptoms include night blindness and loss of peripheral vision. The predisposing factors include autosomal dominant inheritance, autosomal recessive inheritance, and x-linked inheritance. The Retinitis Pigmentosa pipeline drugs market research report provides comprehensive information on the therapeutics under development for Retinitis Pigmentosa, complete with analysis by stage of...
-
Product Insights
Wilson Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Wilson disease is a rare autosomal recessive inherited disorder of copper metabolism that is characterized by excessive deposition of copper in the liver, brain, and other tissues. Symptoms include abdominal pain, jaundice, problems with speech and swallowing, and muscle stiffness. Treatment includes chelators and Vitamin E supplements. The Wilson disease pipeline market research report provides comprehensive information on the therapeutics under development for Wilson disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of...
-
Product Insights
Sicca Syndrome (Sjogren) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Sicca Syndrome or Sjogren's syndrome is an autoimmune disease. It involves inflammation of glands and other tissues of the body. Symptoms include skin rashes or dry skin, vaginal dryness, persistent dry cough, prolonged fatigue, dry eye, dry mouth, joint pain, swelling, and stiffness. Predisposing factors include age, sex, and rheumatic disease. The Sicca Syndrome pipeline drugs market research report provides comprehensive information on the therapeutics under development for Sicca Syndrome, complete with analysis by stage of development, drug target, mechanism...
-
Product Insights
Net Present Value Model: Botaretigene Sparoparvovec
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Botaretigene Sparoparvovec Drug Details AAV-RPGR is...